Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (NASDAQ: HBIO) is a life science tools company that develops, manufactures and sells technologies, products and services used in research, drug and therapy discovery, bio‑production and preclinical testing. News about Harvard Bioscience often centers on how its laboratory instruments and platforms support life science applications for academic institutions, government laboratories, pharmaceutical companies, biotechnology firms and contract research organizations.
Investors and researchers following HBIO news will find regular updates on quarterly financial results, including revenues, gross margins, net income or loss, adjusted EBITDA and cash flows from operations, as reported in the company’s earnings press releases. These announcements are typically accompanied by guidance ranges for upcoming quarters and commentary on demand trends, backlog and operational discipline.
Harvard Bioscience news also covers capital structure and financing developments. In 2025, the company reported amendments to its existing credit agreement, discussions with lenders, and the execution of a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, along with associated warrants and board nomination rights. These items appear in both press releases and Form 8‑K filings and are relevant to readers tracking the company’s liquidity, debt profile and going‑concern considerations.
Another theme in HBIO coverage is corporate governance and leadership changes. The company has announced a CEO succession plan, the appointment of new independent directors, and the designation of a lead independent director. Additional news items describe board appointments linked to financing arrangements and changes in audit committee composition. Operational news has included expanded distribution agreements for laboratory equipment with a major scientific supplier and references to technologies such as pumps, spectrophotometers, BTX electroporation systems and Mesh MEA organoid platforms.
For readers interested in HBIO, this news stream provides context on the company’s financial performance, governance, listing status on Nasdaq, and its role in supplying tools for life science research and preclinical testing. Regular updates can help observers understand how Harvard Bioscience is managing its business and capital structure while serving global life science customers.
Harvard Bioscience (Nasdaq: HBIO) reported Q4 2025 revenue $23.7M and full-year 2025 revenue $86.6M with gross margins of 59.7% (Q4) and 57.7% (FY). The company posted a $56.7M net loss in 2025, driven largely by a $48.0M goodwill impairment, and reported Adjusted EBITDA $8.1M for 2025. Mark Frost was named permanent CFO. Management issued 2026 guidance: Q1 revenue $20.0M–$22.0M and full-year revenue growth of 2%–4%, with adjusted gross margin 58%–60% and adjusted EBITDA growth 6%–10%.
Harvard Bioscience (NASDAQ: HBIO) announced a 1-for-10 reverse stock split approved March 6, 2026, effective 4:30 p.m. ET on March 13, 2026, with post-split trading expected March 16, 2026.
The Reverse Split will convert every ten shares into one, reduce outstanding shares from ~44,719,894 to ~4,471,989, leave total authorized shares unchanged, and proportionally adjust options, warrants, and convertible securities.
No fractional shares will be issued; fractional holders will receive cash in lieu based on the March 13, 2026 closing price as adjusted for the split.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.
A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET, with an audio-only webcast option available via the events and presentations section.
Harvard Bioscience (Nasdaq: HBIO) will announce financial results for the quarter ended December 31, 2025 before the market opens on March 12, 2026.
The company will host an earnings conference call at 8:00 AM Eastern Time; registration is required for participants who wish to ask questions and an audio-only webcast will be available on the investor website.
Harvard Bioscience (NASDAQ: HBIO) reported preliminary Q4 2025 results and outlined a long-term translational science strategy. Q4 revenue $23.7M (above midpoint), gross margin 60% (high end) and adjusted EBITDA $3.8M (+27% YoY). The company targets year‑over‑year revenue growth and mid‑to‑high single‑digit EBITDA growth in 2026 while prioritizing new high‑margin platforms, consumables expansion (55% recurring mix) and operational consolidation, supported by recent debt refinancing and U.S. manufacturing consolidation. Full FY2025 results and a conference call are scheduled for March 12, 2026.
Harvard Bioscience (Nasdaq: HBIO) announced a strategic consolidation of manufacturing to improve efficiency and support long-term growth. The Company will close its Holliston, MA plant, shift U.S. production to Minneapolis, and relocate certain operations to Germany, Sweden, and the UK.
The Holliston site will operate through 2026 with completion targeted by Q1 2027. The initiative is expected to yield approximately $3 million in savings in 2027 and about $4 million in annual savings thereafter, while generating transition-related operating expenses in 2026 and early 2027.
Harvard Bioscience (NASDAQ: HBIO) completed a refinancing and secured a $40.0 million credit facility from BroadOak on Dec 17, 2025 to repay existing debt, strengthen liquidity and extend maturities.
The package includes Term Loan A & B totaling $32.5M, and Term Loan C of $7.5M convertible at $1.00 per share; all loans mature on Dec 17, 2029. Quarterly amortization begins Dec 31, 2027. BroadOak received warrants for 2.0M shares at $0.50 and a board nomination; Bill Snider joined the board effective Dec 17, 2025.
Harvard Bioscience (Nasdaq: HBIO) reported Q3 2025 revenue of $20.6M, gross margin of 58.4%, and a net loss of $1.2M. Adjusted EBITDA for Q3 was $2.0M and cash provided by operations was $1.1M. For the nine months ended Sept 30, 2025, revenue was $62.8M and net loss was $53.8M, driven primarily by a $48.0M goodwill impairment in Q1. The company says it expects to refinance or repay its credit agreement in Q4 2025 and provided Q4 2025 guidance of $22.5M–$24.5M revenue with gross margin of 58%–60%.
The company also reported the highest backlog in nearly two years and four consecutive months of order growth, and will host a webcast and conference call on Nov 6, 2025.
Harvard Bioscience (NASDAQ: HBIO) will report financial results for the quarter ended September 30, 2025 before market open on November 6, 2025. The company will host a conference call to discuss results at 8:00 AM Eastern Time on the same day.
Participants who wish to ask questions must register to receive dial-in numbers and a unique PIN. An audio-only webcast will be available via the company’s Investor Relations events and presentations page. The earnings release and related slide presentation will be posted in the Investor Relations section.
Harvard Bioscience (Nasdaq: HBIO) has expanded its distribution agreement with Fisher Scientific to include the United States market, building upon their existing European partnership. The expanded agreement enables Fisher Scientific to distribute Harvard Bioscience's pumps, spectrophotometers, and BTX electroporation systems throughout the U.S.
The strategic expansion gives Harvard Bioscience access to hundreds of Fisher Scientific sales representatives and their extensive U.S. distribution network. The partnership will offer both established product lines and emerging technologies, including the Mesh MEA for advanced organoid research. This collaboration aims to enhance customer experience through streamlined ordering, faster delivery, and localized support.